One Week on24 Apr 2018 10:26
So its been a week since the P3 results and we have all had time to weigh up the pro's and cons.
The facts are that they tried to go it alone with a P3 (which is to be respected), however it didn't quite work out the way they hoped.
The drug didn't fail. I'll say that bit again - the drug didn't fail. What it did do was create doubt and that is something the market doesn't like.
We know that:
1. There has been some interesting positive results in the P3 trial.
2. Immupharma have been talking to potential partners. These talks will now likely be around how the split is going to work for either another P3 trial or an attempt to commercialise the drug.
3. There was plenty of interest and �10m was raised @ �1.44 per share.
4. The company have announced that they will be analysing the results and updating share holders over the coming weeks.
5. We are awaiting results of the extended trial outside of P3.
Possible scenarios are:
1. Rerun of P3 trial in partnership with another pharma.
2. Partnership with another pharma to bring the drug to market.
3. Total abandonment of Lupuzor (very unlikely)
Either way the market is reacting as it should. It has found a price that they are comfortable with until there is any further update.
There is plenty still to play out here and the potential upside to the share price we already know is good, as it was at �1.80 prior to results.
In the meantime lets hope the board don't dig their heels in and demand an unreasonable deal from any interested parties.